Equities analysts predict that Cerecor Inc (NASDAQ:CERC) will post $4.77 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Cerecor’s earnings, with the lowest sales estimate coming in at $4.24 million and the highest estimate coming in at $5.30 million. Cerecor reported sales of $4.08 million in the same quarter last year, which would suggest a positive year over year growth rate of 16.9%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Cerecor will report full-year sales of $0.00 for the current financial year. For the next financial year, analysts forecast that the firm will post sales of $22.80 million, with estimates ranging from $22.60 million to $23.00 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Cerecor.

A number of research analysts recently issued reports on CERC shares. TheStreet lowered Cerecor from a “c-” rating to a “d+” rating in a report on Wednesday, May 29th. ValuEngine raised Cerecor from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Maxim Group set a $10.00 target price on Cerecor and gave the stock a “buy” rating in a report on Friday. HC Wainwright set a $11.00 price target on Cerecor and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, LADENBURG THALM/SH SH reiterated a “buy” rating and issued a $8.00 price target on shares of Cerecor in a research report on Tuesday, July 2nd. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Cerecor has an average rating of “Buy” and a consensus target price of $9.67.

In related news, major shareholder Armistice Capital Master Fund purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 7th. The stock was acquired at an average price of $4.88 per share, for a total transaction of $48,800.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Armistice Capital, Llc purchased 18,200 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average price of $4.64 per share, with a total value of $84,448.00. The disclosure for this purchase can be found here. Insiders purchased a total of 184,128 shares of company stock valued at $874,662 in the last quarter. 64.30% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp boosted its position in Cerecor by 47.4% during the 2nd quarter. Northern Trust Corp now owns 55,971 shares of the company’s stock worth $304,000 after acquiring an additional 17,999 shares during the period. Bank of New York Mellon Corp boosted its position in Cerecor by 294.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 57,428 shares of the company’s stock worth $312,000 after acquiring an additional 42,885 shares during the period. Charles Schwab Investment Management Inc. acquired a new stake in Cerecor during the 2nd quarter worth about $288,000. JPMorgan Chase & Co. boosted its position in Cerecor by 612.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 72,670 shares of the company’s stock worth $355,000 after acquiring an additional 62,473 shares during the period. Finally, Wells Fargo & Company MN acquired a new stake in Cerecor during the 2nd quarter worth about $853,000. Hedge funds and other institutional investors own 54.18% of the company’s stock.

NASDAQ:CERC traded up $0.12 during mid-day trading on Thursday, reaching $3.35. 65,792 shares of the stock were exchanged, compared to its average volume of 132,936. The business’s fifty day moving average price is $4.51. Cerecor has a 1-year low of $2.71 and a 1-year high of $7.65. The company has a quick ratio of 0.91, a current ratio of 0.95 and a debt-to-equity ratio of 0.62.

About Cerecor

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.

See Also: Oversold

Get a free copy of the Zacks research report on Cerecor (CERC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.